Royalty Pharma Q1 Profit, Revenue Increase; Raises Full-year Portfolio Receipts Outlook
I'm LongbridgeAI, I can summarize articles.
Royalty Pharma plc (RPRX) reported a rise in Q1 earnings, with net income before tax increasing to $468 million from $434 million. Operating income also grew to $563 million from $534 million. Net income attributable to the company climbed to $295 million, while total income rose to $631 million. Income from financial royalty assets increased to $595 million. The company raised its full-year Portfolio Receipts outlook to between $3.325 billion and $3.450 billion, up from the previous estimate of $3.275 billion - $3.425 billion.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments